Skip to content

Advertisement

  • Oral presentation
  • Open Access

ECLip-the European consortium on lipodystrophies: an update

Orphanet Journal of Rare Diseases201510(Suppl 2):O32

https://doi.org/10.1186/1750-1172-10-S2-O32

Published: 11 November 2015

Keywords

  • Research Group
  • Policy Maker
  • Clinical Care
  • Main Research
  • Affected Individual

The European Consortium of Lipodystrophies (ECLip) is a network of relevant clinical and basic-science research groups in Europe involved in investigation of Lipodystrophic Syndromes (LS).

The goal of this Consortium is to enable intensive and effective collaboration among the various high-quality European research groups in order to promote the free exchange of ideas and information concerning research and clinical care among LS researchers. The principal benefit will be the advancement of patient care. It will also promote the public understanding of LS and its consequences in affected individuals. On the other hand, ECLip will lead to further growth and inclusion of novel aspects of LS research, making European investigators the leaders in this important but still poorly explored research area. Likewise, ECLip will try to give visibility and recognition of LS in society and among policy makers, and will help the promotion of advocacy groups in Europe and worldwide.

To date, ECLip is formed by 38 research groups coming from 15 European countries.

The ECLip website (http://www.european-lipodystrophies.org) provides information on all groups involved in the consortium, with information about the researchers, the main research lines of each group, their clinical and basic research facilities, and contact details.

Authors’ Affiliations

(1)
Member of ECLip Executive Board, Division of Endocrinology and Nutrition, University Clinical Hospital of Santiago de Compostela, Santiago de Compostela, Spain

Copyright

© Araújo-Vilar 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement